WIA
CDTX

Wetzel Investment Advisors’s Cidara Therapeutics CDTX Stock Holding History

Wetzel Investment Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,000
Closed -$3.68K – 242
2024
Q2 		$3.68K Buy
4,000
+3,800
+1,900% +$52K ﹤0.01% 634
2024
Q1 		$2.89K Hold
200
– – ﹤0.01% 776
2023
Q4 		$3K Buy
+200
New +$3.21K ﹤0.01% 766

Other funds holding CDTX

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $390M AUM 96.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wetzel Investment Advisors's CDTX Position: Q3 2024 in Review

Wetzel Investment Advisors sold out of Cidara Therapeutics (CDTX) in Q3 2024, closing a stake of 4,000 shares — an estimated $3.68K sold.

Wetzel Investment Advisors first reported a position in CDTX in Q4 2023 and held it in 3 quarters. The position peaked at $3.68K in Q2 2024. 27 funds tracked by Wall St. Rank hold CDTX as of Q3 2024.

  • Wetzel Investment Advisors reported no remaining Cidara Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Wetzel Investment Advisors sold 4,000 Cidara Therapeutics shares in Q3 2024, an estimated $3.68K.
  • Wetzel Investment Advisors first reported a position in Cidara Therapeutics in Q4 2023 and held it in 3 quarters.
  • Wetzel Investment Advisors's Cidara Therapeutics position peaked at $3.68K in Q2 2024.
  • 27 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2024.

Based on Wetzel Investment Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.